We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

Press releases

  • 09/23/2016

    Switzerland's AC Immune opens for trading on NASDAQ

  • 09/22/2016

    AC Immune announces pricing of upsized initial public offering

  • 09/13/2016

    AC Immune commences proposed initial public offering of common shares

  • 07/07/2016

    AC Immune to receive milestone payment for Anti-Tau Antibody moving into Phase 1 trial for Alzheimer’s disease

    • AC Immune to receive second milestone payment of CHF14 million under collaboration agreement with Genentech
  • 05/09/2016

    AC Immune raises USD 43.5 million (CHF 42.7 million) in financing round E

  • 04/18/2016

    AC Immune announces a research and development collaboration in neurodegenerative diseases with Biogen

    • R&D collaboration to develop PET-ligands for two protein targets involved in pathogenesis of neurodegenerative diseases - alpha-synuclein and TDP43
  • 04/05/2016

    AC Immune announces publication of ground-breaking scientific publication on anti-Abeta vaccine in preclinical model of Down syndrome

    • Vaccine demonstrates efficacy in established model for Down syndrome
    • Paper published in PLOS ONE, highly respected peer review journal
    • Start of patient recruitment in clinical trial with vaccine for Alzheimer’s characteristics in people with Down syndrome
  • 01/07/2016

    World’s first clinical trial for anti-Abeta vaccine targeting Alzheimer’s disease-like characteristics in people with Down syndrome

    • Studies AC Immune’s ACI-24, the first anti-amyloid vaccine for treatment of Alzheimer’s disease-like characteristics in people with Down syndrome
    • Clinical Study is done in collaboration with University of California San Diego
    • US NIH provides significant funding with an additional grant from the LuMind Research Down Syndrome Foundation
    • Alzheimer’s disease-like characteristics develop in virtually all people with Down syndrome over age 40; majority develops associated dementia over
      age 60
  • 09/23/2015

    AC Immune signs collaboration agreement with Nestlé Institute of Health Sciences to develop Alzheimer’s disease diagnostic

    • Development of minimally invasive Tau diagnostic assay for Alzheimer’s disease
    • Potential to identify Alzheimer’s patients at very early and potentially pre-symptomatic stage of the disease
    • Neurodegenerative expertise endorsed by fourth Tau collaboration
  • 07/22/2015

    AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer’s disease

    • Phase III clinical program to evaluate crenezumab in people with prodromal-to-mild Alzheimer’s disease
    • AC Immune receives milestone under 2006 collaboration with Genentech 
  • 07/13/2015

    AC Immune receives milestone in Anti-Tau Antibody collaboration with Genentech

    • Lead candidate selected for further development towards clinical trials
    • Encouraging pre-clinical efficacy, safety and pharmacological properties
  • 02/12/2015

    AC Immune Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research

    • Grant to fund development of Parkinson’s disease diagnostic agent
    • Focuses on alpha-synclein, a key protein in Parkinson’s disease pathology
    • Offers potential of earlier and more accurate diagnosis of Parkinson’s disease
  • 01/12/2015

    AC Immune Enters into a Worldwide License and Collaboration Agreement for Alzheimer’s Disease Therapeutic anti-Tau Vaccines with Janssen Pharmaceuticals, Inc.

    • Exclusive worldwide license agreement potentially worth up to USD 509 million (CHF 500 million*)
    • Three-year joint program to develop therapeutic vaccines for tauopathies
    • Therapeutic vaccines offer the potential to treat Alzheimer’s patients earlier in the disease
  • 07/16/2014

    Crenezumab Phase II cognition data in Alzheimer’s disease presented

    • Two phase II studies in people with mild-to-moderate Alzheimer’s disease over 18 months and a total of 522 patients
    • The proof of concept ABBY study met overall objective of estimating treatment effects and demonstrated positive trends in cognitive endpoints over time, although the study did not meet its co-primary endpoints
    • Larger effects seen in patients with mild disease on high-dose of crenezumab intravenously
    • Acceptable risk benefit profile
    • Next steps to be determined by Roche following further analysis of data
  • 05/12/2014

    AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer’s disease

    • Potential important step towards better diagnosis and clinical management of Alzheimer’s disease
    • Tau diagnostics complement AC Immune’s therapeutic product pipeline
    • Piramal Imaging initiates Tau-PET-Imaging tracer development program
    • Significant License Agreement signals the importance of the development of Alzheimer’s Tau-PET-Imaging tracers 
  • 01/09/2014

    AC Immune raises CHF 20 million and initiates world's first anti-pTau vaccine trial for Alzheimer's disease

    • CHF 20 million round D secured from existing investors
    • World's first Alzheimer's vaccine trial against phospho-Tau hallmark
  • 12/23/2013

    Alzheimer's Prevention Initiative (API) Trial marks milestone

    • Participants now enrolled for major prevention trial in Colombia in cognitively healthy adults
  • 01/31/2013

    AC Immune to discontinue development of ACI-91 small molecule

    • Phase II results do not demonstrate efficacy of ACI-91 in patients with advanced Alzheimer's disease
    • ACI-91 drug in-licensed with different mode-of-action from in-house therapies under development
  • 11/12/2012

    FierceBiotech & Recognition of Prof. Pfeifer's personal qualities

  • 09/19/2012

    AC Immune Named One of "Fierce 15" Leading Biotech Companies of 2012

  • 06/18/2012

    AC Immune and Genentech Enter into Second Antibody Collaboration for Alzheimer’s Disease

    • New antibody program targets Tau protein, a major cause of Alzheimer’s disease
    • License agreement potentially worth more than Swiss Francs 400 Million (approximately USD 418 million*)
    • Continuation of excellent long-term partnership based on development of crenezumab anti-Abeta antibody now in Phase II
    • Goal to develop best-in-class and first-in-class antibodies for treatment and diagnosis of Alzheimer’s disease
  • 05/16/2012

    AC Immune Therapy chosen for groundbreaking Alzheimer´s Disease Trial in Colombia and USA

    • World's first Alzheimer's disease prevention trial before onset of symptoms in highest-risk individuals
    • Trial funded by National Institutes of Health, Banner Alzheimer's Institute and Genentech
    • Antibody discovered by AC Immune and exclusively licensed to Genentech
  • 01/17/2012

    Development of new medicines for memory impairment

  • 05/09/2011

    AC Immune recieves significant milestone payment from Genentech

    •  Start of Phase II trial of anti-Abeta antibody for Alzheimer’s Disease
  • 05/31/2010

    Prof. Andrea Pfeifer represents Switzerland at the election of the Ernst & Young World Entrepreneur Of Year

  • 01/14/2010

    AC Immune boosts its preclinical Alzheimer´s pipeline

    • In-licensing of promising memory enhancer ACI-518 from State University of Moscow to complement Alzheimer´s disease drug pipeline
    • Proprietary Morphomer™ ACI-636 enters preclinical development
  • 10/24/2009

    Prof. Andrea Pfeifer - CEO of AC Immune - awarded Swiss Life Science/High-Tech Entrepreneur of the Year 2009

    • Recognition of personal qualities and successful development of thriving biopharmaceutical company
  • 10/08/2009

    AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer’s Disease

    • Bayer´s diagnostic will be used in Phase I clinical trial of AC Immune Alzheimer´s vaccine ACI-24
  • 01/26/2009

    AC Immune Shapes its Future as World Economic Forum Technology Pioneer 2009

    • CHF 40 million raised in successful round C
    • Key appointments of Chief Financial Officer and Chief Medical Director
  • 12/04/2008

    Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development

    • AC Immune selected as Technology Pioneer 2009 by the Word Economic Forum
    • Phase II clinical trial for small molecule ACI-91 approved
    • First patient enrolled in phase I study of Anti-Abeta antibody - Milestone payment received from collaborator Genentech
  • 12/07/2006

    Genentech and AC Immune: Exclusive License Agreement

  • 05/11/2005

    AC Immune raises CHF 21 million in private financing round